Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine development. Investors saw the mRNA biotech company, in particular, as a ...

Baillie Gifford & Co, an independent investment management firm, released its third-quarter 2026 investor letter for “US Equity Growth Strategy”. The letter can be downloaded here. While AI safety and ...

Few large biotech stocks have rewarded patience like Moderna (NASDAQ:MRNA | MRNA Price Prediction), and the size of that run ...

Moderna shares gained 18% last week—finishing it at their highest level in more than four years—after the New York Times ...

Moderna stock popped 9% on Friday after the New York Times reported new details about an effort to speed up cancer vaccine ...

After a few years of stagnation, this stock is soaring.

Moderna's NASDAQ 100 debut triggered a surge in buying, but the real question is whether the rally holds once index funds ...

Moderna ( MRNA) rose roughly 5% and Eli Lilly ( LLY) added nearly 3% to rank among the day’s best-performing stocks in the ...

Moderna stock rallied by triple digits on Aug. 19 with positive news for its cancer vaccine. Is mRNA ready to return to the ...

Moderna (MRNA) stock surged 14% after reports of a new NIH cancer research initiative and encouraging trial data with Merck.

In the recent earnings report, Moderna reiterated its forecast for as much as 10% revenue growth in the current year thanks ...

That came after Moderna and Merck announced their personalized cancer vaccine helped cut the recurrence of melanoma—a form of skin cancer—in a late-stage trial involving more than 1,100 patients, and ...